Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary, Beijing Minhai Biological Technology Co., Ltd., has initiated a Phase I clinical trial of its self‑developed adsorbed acellular DTaP (component) combination vaccine (for adults, adolescents, and children), with the first subject successfully enrolled – advancing a candidate for which no related product from any domestic manufacturer has been approved for marketing in China.
Trial Milestone
| Item | Detail |
|---|---|
| Sponsor | Beijing Minhai Biological Technology Co., Ltd. (wholly‑owned subsidiary of Shenzhen Kangtai Biological Products, SHE: 300601) |
| Product | Adsorbed acellular DTaP (component) combination vaccine (for adults, adolescents, and children) |
| Trial Phase | Phase I – first subject enrolled |
| Initiation Date | 12 Oct 2026 |
| Study Objective | Evaluate safety and immunogenicity in healthy individuals |
| Study Population | Healthy individuals aged 6 years and older |
Vaccine Profile & Mechanism of Action
- Product Type: Adsorbed acellular DTaP (component) combination vaccine, self‑developed by Beijing Minhai – an acellular, component‑based combination formulation designed to protect against three diseases in a single vaccination.
- Target Diseases: After vaccination, the candidate induces an immune response to prevent pertussis (whooping cough), diphtheria and tetanus.
- Broad Age Coverage: Designed for adults, adolescents and children, with the Phase I trial enrolling healthy individuals aged 6 years and older.
- Acellular Design: As an acellular component vaccine, it uses purified bacterial antigen components rather than whole‑cell organisms – the modern standard associated with improved reactogenicity profiles compared with whole‑cell pertussis formulations.
- Domestic Novelty: No related adsorbed acellular DTaP (component) combination vaccine (for adults, adolescents, and children) from any domestic manufacturer has been approved for marketing in China, positioning the candidate as a potential first of its kind domestically.
Clinical Trial Design – Phase I
- Primary Focus: The Phase I trial will evaluate the safety and immunogenicity of the vaccine in healthy individuals aged 6 years and older.
- Status: First subject successfully enrolled, marking formal entry into clinical development; trial site details, sample size and timeline were not disclosed.
Disease Landscape – Pertussis, Diphtheria & Tetanus
- Pertussis: Whooping cough remains a persistent public‑health challenge, with waning vaccine‑induced immunity in adolescents and adults driving resurgent transmission to vulnerable infants in many markets.
- Diphtheria & Tetanus: Both are vaccine‑preventable diseases requiring sustained population immunity and periodic booster coverage across the lifespan.
- Unmet Need in China: The absence of any domestically approved adsorbed acellular DTaP (component) combination vaccine covering adults, adolescents and children highlights a gap in the local vaccine supply chain, currently reliant on other product formats and imported options for broader‑age coverage.
Market Impact & Outlook
- First‑Mover Opportunity: With no domestic competitor product approved, successful development could give Kangtai/Minhai early positioning in a broadly indicated combination vaccine category spanning pediatric, adolescent and adult booster markets.
- Strategic Pipeline Expansion: The Phase I initiation strengthens Shenzhen Kangtai‘s portfolio in combination vaccines, leveraging Beijing Minhai‘s R&D and manufacturing platform.
- Public Health Relevance: An all‑ages DTaP combination vaccine aligns with China’s push to broaden immunization coverage beyond infancy, supporting national infectious‑disease prevention priorities.
- Development Risks: As an early‑stage Phase I asset, the candidate faces a multi‑year clinical and regulatory pathway; progression depends on safety and immunogenicity outcomes and subsequent pivotal trials, none of which are guaranteed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Phase I clinical trial of the adsorbed acellular DTaP (component) combination vaccine by Beijing Minhai Biological Technology, including trial timelines, immunogenicity and safety outcomes, and potential future marketing approval in China. Actual results may differ materially due to risks including clinical trial results, regulatory review requirements, manufacturing scale‑up and competitive dynamics in the vaccine market.-Fineline Info & Tech
